Aankondiging • May 15
electroCore, Inc. Announces Publication in JAMA Highlighting Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia electroCore, Inc. announced the publication of new clinical findings in JAMA Network Open titled, Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, -1.2 points [95% CI, -1.6 to -0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily. Aankondiging • Apr 29
electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026 electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026 Aankondiging • Apr 09
Electrocore Inc Announces First Patient Enrollment in Investigator-Led Study of Gammacore nVNS for PTSD ElectroCore, Inc. announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. The study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incidence of treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The study is anticipated to run for approximately 10 months and is intended to generate preliminary safety and effectiveness data to inform future research in neuropsychiatric applications of nVNS. Aankondiging • Apr 01
ElectroCore Inc Announces Publication Highlighting Benefits Of Non-Invasive Vagus Nerve Stimulation In Patients With Mild Traumatic Brain Injury And PTSD ElectroCore, Inc. announced the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with observed improvements across cognitive, affective, and somatic domains. The study population represented a high-symptom-burden cohort commonly associated with persistent and difficult-to-treat neurobehavioral symptoms. The full article can be accessed here: Frontiers: nVNS for mTBI and PTSD. These findings contribute to the growing body of evidence supporting the therapeutic potential of nVNS in patients with chronic mTBI and comorbid PTSD. Aankondiging • Mar 09
electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026 electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026 Aankondiging • Jan 21
electroCore, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2025 electroCore, Inc. provided earnings guidance for the fourth quarter and year ended December 31, 2025. The company anticipated reporting fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024.
The company anticipated reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million. Aankondiging • Oct 23
electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025 electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025 Aankondiging • Oct 18
electroCore, Inc. announced that it has received $1.856 million in funding On October 17, 2025, electroCore, Inc closed the transaction. the transaction included participation from 3 Investors. Aankondiging • Oct 02
electroCore, Inc. Announces the Publication of A Peer-Reviewed Study in Frontiers in Neurology Demonstrating the Effectiveness of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) in Reducing Persistent Post-Concussion Symptoms electroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). The article, entitled "Non-invasive vagus nerve stimulating is associated with the reduction in persistent post-concussion symptoms: an observational study," found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI). The study included 102 patients with persistent symptoms following mTBI. Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression. Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms. Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury. Aankondiging • Sep 30
electroCore Announces Reimbursement Approval for gammaCore by RIZIV/INAMI in Belgium electroCore, Inc. announced that gammaCore Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV /INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients. This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore's distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries. Aankondiging • Sep 05
electroCore, Inc. Announces Management Changes electroCore, Inc. announced the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. Aankondiging • Sep 04
electroCore, Inc. Announces Board Changes electroCore, Inc. announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore’s Board of Directors, effective September 2, 2025. Ms. Bonfiglioli’s appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (“AI”) transformation initiatives in health providers, payors and Life Sciences’ organizations globally. Since 2023, Ms. Bonfiglioli has been a Member of the Drug Information Association (“DIA”) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East and as advisor for biopharma organizations. Ms. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was one of the founding members of the Holomedicine Association; and Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021. Ms. Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Board of The Women Health Initiative, a community powered by Kearney. She is active in the field of longevity and champions the shift to health enhanced by data and AI. Recent Insider Transactions • Aug 14
Founder & Independent Director recently bought €58k worth of stock On the 11th of August, Thomas Errico bought around 15k shares on-market at roughly €3.85 per share. This transaction amounted to 7.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Thomas has been a buyer over the last 12 months, purchasing a net total of €173k worth in shares. Aankondiging • Aug 12
electroCore, Inc. Announces Appointment of Kelly Benning as Senior Vice President of Truvaga, Effective July 21, 2025 electroCore, Inc. announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder. Aankondiging • Aug 09
electroCore, Inc Provides Earnings Guidance for the Full Year 2025 electroCore, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue to be approximately $30.0 million and net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million. Reported Earnings • Aug 08
Second quarter 2025 earnings released: US$0.44 loss per share (vs US$0.38 loss in 2Q 2024) Second quarter 2025 results: US$0.44 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$7.38m (up 20% from 2Q 2024). Net loss: US$3.67m (loss widened 38% from 2Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Aankondiging • Aug 06
electroCore, Inc. Appoints James C. Theofilos to its Board of Directors, Effective August 1, 2025 electroCore, Inc. announced that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. Mr. Theofilos has been a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation since October 2023. In this role, Mr. Theofilos is the Go-to-Market Finance Lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis. Breakeven Date Change • Aug 01
Forecast to breakeven in 2027 The 4 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$16.4m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • Jul 23
electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025 electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025 Aankondiging • Jul 18
electroCore, Inc., Annual General Meeting, Sep 02, 2025 electroCore, Inc., Annual General Meeting, Sep 02, 2025. Board Change • Jul 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • May 16
Happy Holstein Management, LLC Provides Information to the electroCore, Inc. On May 14, 2025, Happy Holstein Management, LLC announced that they are evaluating the feasibility of a change in the present board of directors or management of electroCore, Inc, including plans or proposals to nominate one or more director candidates, to amend the Company's charter and bylaws to remove the classified board, and other proposals to improve the corporate governance and transparency at the Company. Consistent with their investment purpose and subject to any applicable confidentiality obligations, one or more Happy Holstein Management, LLC or their representatives may engage in communications regarding the Company with other persons, including, without limitation, one or more shareholders of the Company, one or more officers of the Company and/or one or more members of the Board of Directors of the Company. Breakeven Date Change • May 13
Forecast to breakeven in 2027 The 4 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$16.4m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Board Change • May 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • May 08
electroCore, Inc. Provides Preliminary Revenue Guidance for Year Ending December 2025 electroCore, Inc. provided preliminary revenue guidance for year ending December 2025. For the year, the company expects total revenue to be approximately $30.0 million. Aankondiging • Apr 30
electroCore, Inc. to Report Q1, 2025 Results on May 07, 2025 electroCore, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Board Change • Apr 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Apr 04
No longer forecast to breakeven The 3 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.09m in 2026. New consensus forecast suggests the company will make a loss of US$872.7k in 2026. New Risk • Apr 04
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$12m Forecast net loss in 2 years: US$806k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$806k net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€38.3m market cap, or US$42.2m). Board Change • Apr 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Mar 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€55.1m market cap, or US$60.3m). Reported Earnings • Mar 13
Full year 2024 earnings released: US$1.59 loss per share (vs US$3.42 loss in FY 2023) Full year 2024 results: US$1.59 loss per share (improved from US$3.42 loss in FY 2023). Revenue: US$25.2m (up 57% from FY 2023). Net loss: US$11.9m (loss narrowed 37% from FY 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Aankondiging • Mar 06
electroCore, Inc. to Report Q4, 2024 Results on Mar 12, 2025 electroCore, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025 Aankondiging • Mar 01
electroCore, Inc. Announces Resignation of Charles S. Theofilos as A Class III Director of the Board, as A Member of the Compensation Committee of the Board, and as A Member of the Nominating and Governance Commit On February 24, 2025, Charles S. Theofilos, M.D., a member of the Board of Directors of electroCore, Inc. resigned as a Class III director of the Board, as a member of the Compensation Committee of the Board, and as a member of the Nominating and Governance Committee of the Board, in each case effective immediately. In connection with Dr. Theofilos’ resignation, on February 28, 2025, the Board decreased the size of the Board from eight to seven members, effective immediately. Aankondiging • Jan 25
electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Jan 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$677k net loss in 2 years). Aankondiging • Dec 18
electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO). electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO) on December 17, 2024. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) outstanding immediately prior to the Effective Time, shall be cancelled and cease to exist and shall be converted into the right to receive (i) an amount in cash (the “Per Share Cash Consideration’) equal to a pro rata share of the Company’s balance of Net Cash (as determined pursuant to the Merger Agreement) at the Effective Time, after deduction of certain pro rata payments that will be due in accordance with the MRIP (as defined below), without interest and (ii) one contingent value right (a “CVR"), which shall represent the right to receive the Contingent Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. Upon termination of the Merger Agreement under specified circumstances, the NeuroMetrix will be required to pay electroCore a termination fee of $500,000.
Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the approval by the holders of a majority of the outstanding shares of NeuroMetrix Common Stock entitled to vote on the Merger, the determination of Net Cash pursuant to the Merger Agreement, and the filing by the NeuroMetrix of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025.
Ira Kotel and Ilan Katz of Dentons US LLP acted as legal advisors to electroCore. Megan Gates of Covington& Burling LLP acted as legal advisor to NeuroMetrix in the transaction. Aankondiging • Nov 30
electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Nov 15
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.68 loss in 3Q 2023) Third quarter 2024 results: US$0.31 loss per share (improved from US$0.68 loss in 3Q 2023). Revenue: US$6.55m (up 45% from 3Q 2023). Net loss: US$2.50m (loss narrowed 38% from 3Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. New Risk • Nov 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$14m Forecast net loss in 1 year: US$8.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$8.5m net loss next year). Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (€81.8m market cap, or US$86.4m). Aankondiging • Oct 23
electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024 electroCore, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024 Breakeven Date Change • Aug 11
Forecast to breakeven in 2026 The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 48% per year to 2025. The company is expected to make a profit of US$1.49m in 2026. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Reported Earnings • Aug 09
Second quarter 2024 earnings released: US$0.38 loss per share (vs US$1.03 loss in 2Q 2023) Second quarter 2024 results: US$0.38 loss per share (improved from US$1.03 loss in 2Q 2023). Revenue: US$6.14m (up 73% from 2Q 2023). Net loss: US$2.66m (loss narrowed 46% from 2Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Aankondiging • Jul 31
electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024 electroCore, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024 Aankondiging • Jul 18
electroCore, Inc., Annual General Meeting, Sep 03, 2024 electroCore, Inc., Annual General Meeting, Sep 03, 2024. Aankondiging • Jun 26
electroCore Announces the Commercial Launch of TAC-STIM™? electroCore, Inc. announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™?, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STim is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and tactics (BOOST) program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects. Key benefits of TAC-STIM include: Improve performance and combat fatigue for 12-24 hours under extreme conditions; 20-35% faster learning of complex material; Enhance ability to multi-task; Significantly decreased fatigue and increased focus. New Risk • May 24
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$12m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$12m). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (€38.2m market cap, or US$41.5m). Reported Earnings • May 09
First quarter 2024 earnings released: US$0.53 loss per share (vs US$1.24 loss in 1Q 2023) First quarter 2024 results: US$0.53 loss per share. Revenue: US$10.9m (up 292% from 1Q 2023). Net loss: US$7.01m (loss widened 20% from 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. Aankondiging • May 06
electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance electroCore, Inc. announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment. Aankondiging • May 03
electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024 electroCore, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024 Aankondiging • Apr 30
electroCore, Inc. Announces Results of Truvaga Plus Consumer Study electroCore, Inc. announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home twice a day for 30 days to assess the product's benefits, efficacy, and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 82% felt calmer; 82% felt mentally healthier; 77% felt more alert; 77% felt more relaxed; 74% felt they sleep better; 74% felt their mood improved; and 67% had more energy. Of those that felt they slept better, 72% reported they received between 30 minutes to 2+ hours or more sleep each night. After the study completed, 87% of users said they were likely to continue to use Truvaga Plus for ongoing overall wellness benefits. Aankondiging • Apr 10
electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness electroCore, Inc. announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Key features of Truvaga Plus include: Mobile App Connectivity: Empowering users to control sessions, plan schedules, and track progress conveniently through integrated mobile application. Unlimited Sessions: Providing users with the flexibility for prolonged usage and extended benefits, ensuring continuous support for achieving optimal wellness. Rechargeable: Enhancing sustainability and user convenience, Truvaga Plus features a rechargeable design for uninterrupted usage. Compact Design: Sleeker, smaller, and more portable, the new design of Truvaga Plus ensures enhanced user comfort and convenience. Reported Earnings • Mar 15
Full year 2023 earnings released: US$3.42 loss per share (vs US$4.69 loss in FY 2022) Full year 2023 results: US$3.42 loss per share (improved from US$4.69 loss in FY 2022). Revenue: US$16.0m (up 87% from FY 2022). Net loss: US$18.8m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Aankondiging • Mar 06
electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024 electroCore, Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024 Breakeven Date Change • Feb 22
Forecast to breakeven in 2026 The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.10m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule. Breakeven Date Change • Feb 21
Forecast to breakeven in 2026 The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.10m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule. Breakeven Date Change • Feb 21
Forecast to breakeven in 2026 The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.10m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule. 
